Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667090> ?p ?o ?g. }
- W4385667090 endingPage "e50253dc" @default.
- W4385667090 startingPage "e50253dc" @default.
- W4385667090 abstract "Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: A novel genomically defined subset of non-APL AML and MDS patients with RARA gene overexpression was identified with an actionable target for tamibarotene (formerly SY-1425), an oral and selective RARα agonist. RARA overexpression is detectable by a blood-based biomarker test. In newly diagnosed (ND) unfit AML patients with RARA overexpression, tamibarotene/azacitidine treatment is associated with a 61% composite CR rate; median time to response was 1.2 months. In previous analyses, RARA overexpression was not correlated with mutations likely to confer prognostic risk (McKeown 2017, de Botton 2022). However, molecular characterization of this novel disease subset is ongoing. Aims: Further characterize the molecular profile of AML and MDS patients positive for RARA overexpression in a Phase 2 multicenter trial SY-1425-201 (NCT02807558). Methods: ND unfit AML patients and patients with relapsed/refractory (R/R) AML and MDS were screened for RARA overexpression. For RARA-positive patients, IPSS-R risk category (MDS patients), and AML/MDS subtype were recorded. Pretreatment peripheral blood mononuclear cells from a subset of AML and MDS patients with RARA overexpression were analyzed by NGS for 40 somatic DNA mutations (Oncomine Myeloid Assay Gx – ThermoFisher). Results: 115 RARA-positive patients (80 AML, 35 MDS; median age 74; 57% male) were enrolled between September 2016 and May 2020. 80 RARA-positive AML patients had clinical annotation: 56 with R/R and 24 with ND unfit AML. Overall, 5% of patients (4/80) had therapy-related AML and 6% of patients (5/80) had secondary AML. 70 enrolled RARA-positive AML patients had NGS data: 51 with R/R and 19 with ND unfit AML. Mutation frequencies for the AML cohorts were generally similar to those described in published series. Frequencies for the R/R AML cohort included: 25% CEBPA, 22% RUNX1, 22% BCOR, 18% TET2, 16% TP53, 16% DNMT3A, 14% SRSF2, 12% IDH2, 10% SF3B1, and 8% FLT, and 18 other variants in four or fewer patients each. Frequencies for the ND unfit AML cohort included: 26% SRSF2, 21% RUNX1, 16% NPM1, 11% TET2, 11% TP53, 11% IDH2, 11% PTPN11, 11% NRAS, and 8 other variants in 1 patient each. Mutation data were available for 6 patients with RARA-positive R/R MDS (3 IPSS-R high and 3 very high-risk disease). Pathogenic variants included mutations frequently identified in large published MDS datasets: DNMT3A (3 patients), SF3B1 (2 patients), U2AF1 (2 patients), ASXL1 (1 patient), ETV6 (1 patient), NRAS (1 patient), and STAG2 (1 patient). Summary/Conclusion: AML and MDS with RARA overexpression present with molecular features similar to those described in published datasets. Notably, SRSF2 was the most common mutation in the ND older unfit AML cohort, consistent with published series. While the small number of RARA-positive MDS patients precludes definitive characterization of molecular profiles, data in AML patients suggest that RARA overexpression may be agnostic to known molecular features. Further investigation correlating genetic and mutational features in AML and MDS patients positive for RARA overexpression is ongoing in the Phase 2 SELECT-AML-1 trial of tamibarotene/venetoclax/azacitidine and Phase 3 SELECT-MDS-1 trial of tamibarotene/azacitidine, respectively. Keywords: Acute myeloid leukemia, Myelodysplastic syndrome, Mutation analysis" @default.
- W4385667090 created "2023-08-09" @default.
- W4385667090 creator A5001596576 @default.
- W4385667090 creator A5003572390 @default.
- W4385667090 creator A5004760042 @default.
- W4385667090 creator A5014838075 @default.
- W4385667090 creator A5017435311 @default.
- W4385667090 creator A5019538549 @default.
- W4385667090 creator A5023982618 @default.
- W4385667090 creator A5032144639 @default.
- W4385667090 creator A5034488510 @default.
- W4385667090 creator A5045087884 @default.
- W4385667090 creator A5047152348 @default.
- W4385667090 creator A5052564121 @default.
- W4385667090 creator A5061865992 @default.
- W4385667090 creator A5066934816 @default.
- W4385667090 creator A5070277385 @default.
- W4385667090 creator A5076550283 @default.
- W4385667090 creator A5080661528 @default.
- W4385667090 creator A5086805182 @default.
- W4385667090 creator A5089930850 @default.
- W4385667090 creator A5092084860 @default.
- W4385667090 date "2023-08-01" @default.
- W4385667090 modified "2023-09-27" @default.
- W4385667090 title "PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY" @default.
- W4385667090 doi "https://doi.org/10.1097/01.hs9.0000973948.50253.dc" @default.
- W4385667090 hasPublicationYear "2023" @default.
- W4385667090 type Work @default.
- W4385667090 citedByCount "0" @default.
- W4385667090 crossrefType "journal-article" @default.
- W4385667090 hasAuthorship W4385667090A5001596576 @default.
- W4385667090 hasAuthorship W4385667090A5003572390 @default.
- W4385667090 hasAuthorship W4385667090A5004760042 @default.
- W4385667090 hasAuthorship W4385667090A5014838075 @default.
- W4385667090 hasAuthorship W4385667090A5017435311 @default.
- W4385667090 hasAuthorship W4385667090A5019538549 @default.
- W4385667090 hasAuthorship W4385667090A5023982618 @default.
- W4385667090 hasAuthorship W4385667090A5032144639 @default.
- W4385667090 hasAuthorship W4385667090A5034488510 @default.
- W4385667090 hasAuthorship W4385667090A5045087884 @default.
- W4385667090 hasAuthorship W4385667090A5047152348 @default.
- W4385667090 hasAuthorship W4385667090A5052564121 @default.
- W4385667090 hasAuthorship W4385667090A5061865992 @default.
- W4385667090 hasAuthorship W4385667090A5066934816 @default.
- W4385667090 hasAuthorship W4385667090A5070277385 @default.
- W4385667090 hasAuthorship W4385667090A5076550283 @default.
- W4385667090 hasAuthorship W4385667090A5080661528 @default.
- W4385667090 hasAuthorship W4385667090A5086805182 @default.
- W4385667090 hasAuthorship W4385667090A5089930850 @default.
- W4385667090 hasAuthorship W4385667090A5092084860 @default.
- W4385667090 hasBestOaLocation W43856670901 @default.
- W4385667090 hasConcept C104317684 @default.
- W4385667090 hasConcept C126322002 @default.
- W4385667090 hasConcept C127848430 @default.
- W4385667090 hasConcept C143998085 @default.
- W4385667090 hasConcept C150194340 @default.
- W4385667090 hasConcept C190727270 @default.
- W4385667090 hasConcept C2483381 @default.
- W4385667090 hasConcept C2776059313 @default.
- W4385667090 hasConcept C2776239401 @default.
- W4385667090 hasConcept C2778729363 @default.
- W4385667090 hasConcept C2781197716 @default.
- W4385667090 hasConcept C30481170 @default.
- W4385667090 hasConcept C45091340 @default.
- W4385667090 hasConcept C501734568 @default.
- W4385667090 hasConcept C53226629 @default.
- W4385667090 hasConcept C535046627 @default.
- W4385667090 hasConcept C55493867 @default.
- W4385667090 hasConcept C71924100 @default.
- W4385667090 hasConcept C86803240 @default.
- W4385667090 hasConceptScore W4385667090C104317684 @default.
- W4385667090 hasConceptScore W4385667090C126322002 @default.
- W4385667090 hasConceptScore W4385667090C127848430 @default.
- W4385667090 hasConceptScore W4385667090C143998085 @default.
- W4385667090 hasConceptScore W4385667090C150194340 @default.
- W4385667090 hasConceptScore W4385667090C190727270 @default.
- W4385667090 hasConceptScore W4385667090C2483381 @default.
- W4385667090 hasConceptScore W4385667090C2776059313 @default.
- W4385667090 hasConceptScore W4385667090C2776239401 @default.
- W4385667090 hasConceptScore W4385667090C2778729363 @default.
- W4385667090 hasConceptScore W4385667090C2781197716 @default.
- W4385667090 hasConceptScore W4385667090C30481170 @default.
- W4385667090 hasConceptScore W4385667090C45091340 @default.
- W4385667090 hasConceptScore W4385667090C501734568 @default.
- W4385667090 hasConceptScore W4385667090C53226629 @default.
- W4385667090 hasConceptScore W4385667090C535046627 @default.
- W4385667090 hasConceptScore W4385667090C55493867 @default.
- W4385667090 hasConceptScore W4385667090C71924100 @default.
- W4385667090 hasConceptScore W4385667090C86803240 @default.
- W4385667090 hasIssue "S3" @default.
- W4385667090 hasLocation W43856670901 @default.
- W4385667090 hasLocation W43856670902 @default.
- W4385667090 hasOpenAccess W4385667090 @default.
- W4385667090 hasPrimaryLocation W43856670901 @default.
- W4385667090 hasRelatedWork W1979521298 @default.
- W4385667090 hasRelatedWork W2127738065 @default.
- W4385667090 hasRelatedWork W2193596267 @default.
- W4385667090 hasRelatedWork W2734654777 @default.